Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?

Vaccine X(2020)10.1016/j.jvacx.2020.100076Source: DataRank Database

What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? is a research paper published in Vaccine X (2020). On theSindex it has a DataRank of 0. It has been cited 87 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access87 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.89)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Marc K. Hellerstein ORCID

Live enrichment

PubMed:32875286 PMC:PMC7452821 OpenAlex:https://openalex.org/W3081417452

National Institutes of Health

Grant: R01-AI43866

National Institutes of Health

Grant: U19AI057266

NIAID NIH HHS

Grant: R01 AI043866

National Institutes of Health

Grant: 1R01AI043866-01A1

T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPY

National Institutes of Health

Grant: 3U19AI057266-05S1

IMMUNOLOGICAL MEMORY TO VACCINATION

FWCI

1.89

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.jvacx.2020.100076

publisherhttps://doi.org/10.1016/j.jvacx.2020.100076

publisherhttps://api.elsevier.com/content/article/PII:S2590136220300231?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2590136220300231?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32875286

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

AntibodyImmunologyImmunityVirologyImmune systemCoronavirusVaccinationVirusAntigenEpitopeBiologyCellular immunityCD8MedicineDiseaseInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)AntibodiesVaccinesProtective immunitySARST-cellsT-cell EpitopesAntibody-dependent EnhancementYellow Fever VaccineCd8 T-cellsDurable ImmunityCovid-19Sars-cov-2T Cell LifespanReviewSíndrome respiratorio agudo graveGeneral VeterinaryGeneral Immunology and MicrobiologyPublic Health, Environmental and Occupational HealthRC581-607Infectious DiseasesMolecular MedicineImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being